Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.

Lissoni, P; Vaghi, M; Villa, S; Bodraska, A; Cerizza, L; Tancini, G; Gardani, G S

Lissoni, P; Vaghi, M; Villa, S; Bodraska, A; Cerizza, L; Tancini, G; Gardani, G S.

Affiliation

Lissoni P; Division of Radiation, Oncology, San Gerardo Hospital, 20052 Monza, Milan, Italy.

Anticancer Res ; 23(1B): 733-6, 2003.

Article in En | MEDLINE | ID: mdl-12680176

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Breast Neoplasms/drug therapy; Prolactin/antagonists & inhibitors; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Breast Neoplasms/blood; Breast Neoplasms/pathology; Cabergoline; Ergolines/administration & dosage; Ergolines/adverse effects; Female; Humans; Middle Aged; Neoplasm Metastasis; Prolactin/blood; Tamoxifen/administration & dosage; Triptorelin Pamoate/administration & dosage; Triptorelin Pamoate/adverse effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prolactin / Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Anticancer Res Year: 2003 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links